Faknostics, LLC
Publicly observedPhoenix, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Phoenix | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Faknostics, LLC | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | TK5AKDP8CSZ7 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant15 Sept 2024Publicly observed
NIH SBIR/STTR award: Novel Paxillin-FAK Inhibitors for the Treatment of Liver Fibrosis
USD 669,464.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant15 Sept 2024Publicly observed
NIH SBIR/STTR award: Novel Paxillin-FAK Inhibitors for the Treatment of Liver Fibrosis
USD 663,777.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant10 Aug 2022Publicly observed
NIH SBIR/STTR award: Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis
USD 662,561.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
- Grant10 Aug 2022Publicly observed
NIH SBIR/STTR award: Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis
USD 663,310.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.